$17.17
7.09% today
Nasdaq, Apr 03, 06:49 pm CET
ISIN
US07373V1052
Symbol
BEAM
Sector
Industry

Beam Therapeutics Inc Stock price

$18.48
-6.62 26.37% 1M
-5.02 21.36% 6M
-6.32 25.48% YTD
-12.07 39.51% 1Y
-43.88 70.37% 3Y
+3.22 21.10% 5Y
-0.27 1.44% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.85 4.79%
ISIN
US07373V1052
Symbol
BEAM
Sector
Industry

Key metrics

Market capitalization $1.85b
Enterprise Value $1.16b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 18.19
P/S ratio (TTM) P/S ratio 29.05
P/B ratio (TTM) P/B ratio 2.11
Revenue growth (TTM) Revenue growth -83.18%
Revenue (TTM) Revenue $63.52m
EBIT (operating result TTM) EBIT $-415.57m
Free Cash Flow (TTM) Free Cash Flow $-356.19m
Cash position $850.74m
EPS (TTM) EPS $-4.58
P/E forward negative
P/S forward 29.06
EV/Sales forward 18.20
Short interest 15.14%
Show more

Is Beam Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Beam Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Beam Therapeutics Inc forecast:

15x Buy
83%
3x Hold
17%

Analyst Opinions

18 Analysts have issued a Beam Therapeutics Inc forecast:

Buy
83%
Hold
17%

Financial data from Beam Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
64 64
83% 83%
100%
- Direct Costs 22 22
19% 19%
35%
42 42
88% 88%
65%
- Selling and Administrative Expenses 68 68
8% 8%
107%
- Research and Development Expense 368 368
16% 16%
579%
-394 -394
164% 164%
-620%
- Depreciation and Amortization 22 22
19% 19%
35%
EBIT (Operating Income) EBIT -416 -416
135% 135%
-654%
Net Profit -377 -377
184% 184%
-593%

In millions USD.

Don't miss a Thing! We will send you all news about Beam Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Beam Therapeutics Inc Stock News

Positive
Schaeffers Research
2 days ago
Subscribers to  Chart of the Week  received this commentary on Sunday, March 30.
Negative
Invezz
3 days ago
Biotech investors are grappling with fresh uncertainty following the abrupt resignation of Dr. Peter Marks, a key figure in the US Food and Drug Administration.
Neutral
GlobeNewsWire
7 days ago
U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S.
More Beam Therapeutics Inc News

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. It has a research and clinical collaboration agreement with Magenta Therapeutics, Inc. Beam Therapeutics Inc. was founded in 2017 and is based in Cambridge, Massachusetts.

Head office United States
CEO John Evans
Employees 483
Founded 2017
Website www.beamtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today